JP7536424B2 - 多重特異性分子 - Google Patents

多重特異性分子 Download PDF

Info

Publication number
JP7536424B2
JP7536424B2 JP2018563747A JP2018563747A JP7536424B2 JP 7536424 B2 JP7536424 B2 JP 7536424B2 JP 2018563747 A JP2018563747 A JP 2018563747A JP 2018563747 A JP2018563747 A JP 2018563747A JP 7536424 B2 JP7536424 B2 JP 7536424B2
Authority
JP
Japan
Prior art keywords
binding
antibody
vld
bdm
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510812A5 (enExample
JP2019510812A (ja
Inventor
アンソニー・サイモン・ロバーツ
ジョージ・コプシダス
マイケル・ロス・ルーク
フィル・アンソニー・ジェニングス
Original Assignee
イミュネクサス・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900708A external-priority patent/AU2016900708A0/en
Application filed by イミュネクサス・セラピューティクス・リミテッド filed Critical イミュネクサス・セラピューティクス・リミテッド
Publication of JP2019510812A publication Critical patent/JP2019510812A/ja
Publication of JP2019510812A5 publication Critical patent/JP2019510812A5/ja
Priority to JP2022078237A priority Critical patent/JP2022105574A/ja
Priority to JP2023219531A priority patent/JP2024026531A/ja
Application granted granted Critical
Publication of JP7536424B2 publication Critical patent/JP7536424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018563747A 2016-02-26 2017-02-27 多重特異性分子 Active JP7536424B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078237A JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A JP2024026531A (ja) 2016-02-26 2023-12-26 多重特異性分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709 2016-02-26
AU2016900708 2016-02-26
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078237A Division JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子

Publications (3)

Publication Number Publication Date
JP2019510812A JP2019510812A (ja) 2019-04-18
JP2019510812A5 JP2019510812A5 (enExample) 2020-04-09
JP7536424B2 true JP7536424B2 (ja) 2024-08-20

Family

ID=59685848

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563747A Active JP7536424B2 (ja) 2016-02-26 2017-02-27 多重特異性分子
JP2022078237A Pending JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A Pending JP2024026531A (ja) 2016-02-26 2023-12-26 多重特異性分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078237A Pending JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A Pending JP2024026531A (ja) 2016-02-26 2023-12-26 多重特異性分子

Country Status (7)

Country Link
US (4) US20190338013A1 (enExample)
EP (1) EP3419667A4 (enExample)
JP (3) JP7536424B2 (enExample)
CN (1) CN109310766A (enExample)
AU (2) AU2017222700B2 (enExample)
TW (1) TW201734037A (enExample)
WO (1) WO2017143406A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TW201930349A (zh) * 2018-01-08 2019-08-01 大陸商南京傳奇生物科技有限公司 多重特異性抗原結合蛋白及其使用方法
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-1に対する単一ドメイン抗体及びその変異体
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
KR20210131373A (ko) * 2019-02-18 2021-11-02 커리어 테라퓨틱스, 인코포레이티드. 오르토폭스바이러스 주요 조직적합성 복합체(mhc) 클래스 i-유사 단백질(omcp) 및 종양-특이 결합 파트너를 사용한 이중특이적 융합 단백질
JP2022527761A (ja) * 2019-03-26 2022-06-06 フォーティ セブン, インコーポレイテッド がん治療のための多重特異性作用物質
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2023545135A (ja) * 2020-10-12 2023-10-26 グレフェックス, インコーポレイテッド SARS-CoVタンパク質発現細胞に対するT細胞応答を標的にする抗体コンストラクト、それらの設計および使用
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US20250345423A1 (en) * 2021-11-26 2025-11-13 Imunexus Therapeutics Limited Binding domain molecules on cell surfaces
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
EP4615859A2 (en) * 2022-11-09 2025-09-17 Repligen Corporation Affinity agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505103A (ja) 1998-03-06 2002-02-19 ダイアテック・ピーティワイ・リミテッド V様ドメイン結合分子
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2011504742A (ja) 2007-11-30 2011-02-17 グラクソ グループ リミテッド 抗原結合性構築物
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163339A1 (en) * 1999-04-01 2001-12-19 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
HRP20180045T1 (hr) * 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
CA2763493A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505103A (ja) 1998-03-06 2002-02-19 ダイアテック・ピーティワイ・リミテッド V様ドメイン結合分子
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2011504742A (ja) 2007-11-30 2011-02-17 グラクソ グループ リミテッド 抗原結合性構築物
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質

Also Published As

Publication number Publication date
JP2022105574A (ja) 2022-07-14
CN109310766A (zh) 2019-02-05
US20240182542A1 (en) 2024-06-06
TW201734037A (zh) 2017-10-01
US20210230249A1 (en) 2021-07-29
US20210040177A1 (en) 2021-02-11
US20190338013A1 (en) 2019-11-07
AU2017222700B2 (en) 2018-09-27
EP3419667A1 (en) 2019-01-02
EP3419667A4 (en) 2019-10-23
AU2017222700A1 (en) 2018-03-22
WO2017143406A1 (en) 2017-08-31
AU2019200005A1 (en) 2019-01-24
JP2019510812A (ja) 2019-04-18
JP2024026531A (ja) 2024-02-28
US11345736B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
US11345736B2 (en) Multi-specific molecules
US12324837B2 (en) ROR1-specific antigen binding molecules
US11414497B2 (en) Anti-PSMA antibodies and use thereof
US20230293687A1 (en) T cells and chimeric stimulating receptors and uses thereof
US8043621B2 (en) Recombinant fusion protein and polynucleotide construct for immunotoxin production
CA3195675A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
JP2024509910A (ja) Mage-a4ペプチド-mhc抗原結合タンパク質
JP7512413B2 (ja) 抗pd-l1およびpd-l2抗体ならびにその誘導体および用途
US20230167200A1 (en) Platform for constructing multispecific antibody
CN117964767B (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用
CN119060184A (zh) 抗rage抗体及其应用
JP2024546875A (ja) 二連型mhc標的化t細胞エンゲージャー
JP7490559B2 (ja) 抗ラムダ骨髄腫抗原(lma)発現がん及び自己免疫障害を処置するlma結合タンパク質
US20240101680A1 (en) Antibodies Targeting Integrin Beta-2
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
KR20250085636A (ko) 신규 항-myct1 인간항체 및 이의 용도
KR20250001441A (ko) 인간화 항-myct1 항체 및 이의 용도
WO2025148933A1 (zh) 抗体及其药物偶联物和用途
Paton Construction and characterisation of anti-tumour antibody-based proteins for use in diagnostics and therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210405

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220518

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220708

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240807

R150 Certificate of patent or registration of utility model

Ref document number: 7536424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150